Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study
- PMID: 23299844
- PMCID: PMC3541472
- DOI: 10.1136/bmj.e8525
Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study
Abstract
Objectives: To assess whether a double therapy combination consisting of diuretics, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers with addition of non-steroidal anti-inflammatory drugs (NSAIDs) and the triple therapy combination of two of the aforementioned antihypertensive drugs to which NSAIDs are added are associated with an increased risk of acute kidney injury.
Design: Retrospective cohort study using nested case-control analysis.
Setting: General practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database.
Participants: A cohort of 487,372 users of antihypertensive drugs.
Main outcome measures: Rate ratios with 95% confidence intervals of acute kidney injury associated with current use of double and triple therapy combinations of antihypertensive drugs with NSAIDs.
Results: During a mean follow-up of 5.9 (SD 3.4) years, 2215 cases of acute kidney injury were identified (incidence rate 7/10,000 person years). Overall, current use of a double therapy combination containing either diuretics or angiotensin converting enzyme inhibitors or angiotensin receptor blockers with NSAIDs was not associated with an increased rate of acute kidney injury. In contrast, current use of a triple therapy combination was associated with an increased rate of acute kidney injury (rate ratio 1.31, 95% confidence interval 1.12 to 1.53). In secondary analyses, the highest risk was observed in the first 30 days of use (rate ratio 1.82, 1.35 to 2.46).
Conclusions: A triple therapy combination consisting of diuretics with angiotensin converting enzyme inhibitors or angiotensin receptor blockers and NSAIDs was associated with an increased risk of acute kidney injury. The risk was greatest at the start of treatment. Although antihypertensive drugs have cardiovascular benefits, vigilance may be warranted when they are used concurrently with NSAIDs.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at
Comment in
-
Safety of coprescribing NSAIDs with multiple antihypertensive agents: triple drug combinations are associated with increased hospital admission for acute kidney injury,but questions remain.BMJ. 2013 Jan 8;346:e8713. doi: 10.1136/bmj.e8713. BMJ. 2013. PMID: 23299846 No abstract available.
-
A few clarifications please.BMJ. 2013 Feb 19;346:f1015. doi: 10.1136/bmj.f1015. BMJ. 2013. PMID: 23423366 No abstract available.
-
Authors' reply to Moore.BMJ. 2013 Feb 19;346:f1016. doi: 10.1136/bmj.f1016. BMJ. 2013. PMID: 23423367 No abstract available.
-
More evidence of nephrotoxicity with renin-angiotensin-aldosterone system blockers.BMJ. 2013 Feb 19;346:f661. doi: 10.1136/bmj.f661. BMJ. 2013. PMID: 23423371 No abstract available.
-
The nephrotoxic "triple whammy" of combining diuretics, ACE inhibitors, and NSAIDs [corrected].BMJ. 2013 Feb 19;346:f678. doi: 10.1136/bmj.f678. BMJ. 2013. PMID: 23423372 No abstract available.
-
Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury.Evid Based Med. 2013 Dec;18(6):232-3. doi: 10.1136/eb-2013-101273. Epub 2013 Apr 19. Evid Based Med. 2013. PMID: 23604181 No abstract available.
Similar articles
-
Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.Kidney Int. 2015 Aug;88(2):396-403. doi: 10.1038/ki.2015.101. Epub 2015 Apr 15. Kidney Int. 2015. PMID: 25874600
-
More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database.Ren Fail. 2014 Aug;36(7):1166-8. doi: 10.3109/0886022X.2014.917943. Epub 2014 May 15. Ren Fail. 2014. PMID: 24826803
-
Non-steroidal anti-inflammatory drugs, renin-angiotensin system blockade or diuretics and risk of acute kidney injury: A case-crossover study.Arch Gerontol Geriatr. 2024 Aug;123:105394. doi: 10.1016/j.archger.2024.105394. Epub 2024 Mar 26. Arch Gerontol Geriatr. 2024. PMID: 38537386
-
What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis.BMJ Open. 2017 Apr 7;7(4):e012674. doi: 10.1136/bmjopen-2016-012674. BMJ Open. 2017. PMID: 28389482 Free PMC article. Review.
-
Drug Interactions Affecting Kidney Function: Beware of Health Threats from Triple Whammy.Adv Ther. 2022 Jan;39(1):140-147. doi: 10.1007/s12325-021-01939-9. Epub 2021 Nov 29. Adv Ther. 2022. PMID: 34845649 Free PMC article. Review.
Cited by
-
Insomnia and sleep duration for kidney function: Mendelian randomization study.Ren Fail. 2024 Dec;46(2):2387430. doi: 10.1080/0886022X.2024.2387430. Epub 2024 Aug 12. Ren Fail. 2024. PMID: 39132818 Free PMC article.
-
Significantly Positive Impact of Nonsteroidal Anti-inflammatory Drugs Combined With Osmoprotectant (Osmolytes) in Cancer Treatment.Cureus. 2024 Jun 30;16(6):e63529. doi: 10.7759/cureus.63529. eCollection 2024 Jun. Cureus. 2024. PMID: 39086782 Free PMC article. Review.
-
Treatment of chronic kidney disease in older populations.Nat Rev Nephrol. 2024 Sep;20(9):586-602. doi: 10.1038/s41581-024-00854-w. Epub 2024 Jul 8. Nat Rev Nephrol. 2024. PMID: 38977884 Review.
-
Biologically Synthesized Gold Nanoparticles Mitigate Aluminum Chloride-Induced Nephrotoxicity via Downregulation of iNOX, LCN2 and IL-1β Genes.Cell Biochem Biophys. 2024 Sep;82(3):2493-2502. doi: 10.1007/s12013-024-01360-3. Epub 2024 Jun 22. Cell Biochem Biophys. 2024. PMID: 38907938
-
A Drug Safety Briefing (II) in Transplantation from Real-World Individual Pharmacotherapy Management to Prevent Patient and Graft from Polypharmacy Risks at the Very Earliest Stage.Pharmaceuticals (Basel). 2024 Feb 25;17(3):294. doi: 10.3390/ph17030294. Pharmaceuticals (Basel). 2024. PMID: 38543080 Free PMC article. Review.
References
-
- World Health Organization (Europe). Databases. www.euro.who.int/en/what-we-do/data-and-evidence/databases.
-
- Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006;1:43-51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical